StockData
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$12.40−0.64 (-4.91%)

Close on Nov 18, 2026Market cap $460.59MP/E –Yield –

Crescent Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Crescent Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$73.62M. For fiscal 2025 it was -$72.45M. The highest annual figure on record is -$4.49M in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$72.45M–
FY2024Dec 31, 2024-$31.11M–
FY2023Dec 31, 2023-$34.90M–
FY2022Dec 31, 2022-$46.54M–
FY2021Dec 31, 2021-$57.50M–
FY2020Dec 31, 2020-$39.31M–
FY2019Dec 31, 2019-$52.13M–
FY2018Dec 31, 2018-$43.46M–
FY2017Dec 31, 2017-$30.06M–
FY2016Dec 31, 2016-$30.44M–
FY2015Dec 31, 2015-$8.51M–
FY2014Dec 31, 2014-$4.49M–
FY2013Dec 31, 2013-$15.62M–
FY2012Dec 31, 2012-$10.79M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.48M–
Q1 FY2026Mar 31, 2026-$9.08M–
Q4 FY2025Dec 31, 2025-$26.93M–
Q3 FY2025Sep 30, 2025-$18.13M–
Q2 FY2025Jun 30, 2025-$16.54M–
Q1 FY2025Mar 31, 2025-$10.85M–
Q4 FY2024Dec 31, 2024-$3.70M–
Q3 FY2024Sep 30, 2024-$7.99M–
Q2 FY2024Jun 30, 2024-$8.90M–
Q1 FY2024Mar 31, 2024-$10.52M–
Q4 FY2023Dec 31, 2023-$7.62M–
Q3 FY2023Sep 30, 2023-$8.69M–
Q2 FY2023Jun 30, 2023-$6.99M–
Q1 FY2023Mar 31, 2023-$11.61M–
Q4 FY2022Dec 31, 2022-$7.91M–
Q3 FY2022Sep 30, 2022-$8.62M–
Q2 FY2022Jun 30, 2022-$16.27M–
Q1 FY2022Mar 31, 2022-$13.74M–
Q4 FY2021Dec 31, 2021-$12.81M–
Q3 FY2021Sep 30, 2021-$16.95M–
Q2 FY2021Jun 30, 2021-$13.62M–
Q1 FY2021Mar 31, 2021-$14.13M–
Q4 FY2020Dec 31, 2020-$9.72M–
Q3 FY2020Sep 30, 2020-$11.52M–
Q2 FY2020Jun 30, 2020-$14.56M–
Q1 FY2020Mar 31, 2020-$3.51M–
Q4 FY2019Dec 31, 2019-$12.81M–
Q3 FY2019Sep 30, 2019-$13.47M–
Q2 FY2019Jun 30, 2019-$11.47M–
Q1 FY2019Mar 31, 2019-$14.39M–
Q4 FY2018Dec 31, 2018-$10.04M–
Q3 FY2018Sep 30, 2018-$10.11M–
Q2 FY2018Jun 30, 2018-$13.08M–
Q1 FY2018Mar 31, 2018-$10.23M–
Q4 FY2017Dec 31, 2017-$8.40M–
Q3 FY2017Sep 30, 2017-$6.26M–
Q2 FY2017Jun 30, 2017-$6.27M–
Q1 FY2017Mar 31, 2017-$9.12M–
Q4 FY2016Dec 31, 2016-$6.39M–
Q3 FY2016Sep 30, 2016-$7.70M–

More Crescent Biopharma figures

See a number that looks wrong?